Mudita Advisors LLP Has $15.35 Million Stock Position in Establishment Labs Holdings Inc. (NASDAQ:ESTA)

Mudita Advisors LLP grew its position in Establishment Labs Holdings Inc. (NASDAQ:ESTA - Free Report) by 19.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 354,801 shares of the company's stock after acquiring an additional 56,700 shares during the quarter. Establishment Labs makes up approximately 8.4% of Mudita Advisors LLP's holdings, making the stock its 5th largest position. Mudita Advisors LLP owned 1.27% of Establishment Labs worth $15,352,000 at the end of the most recent quarter.

Several other large investors have also recently added to or reduced their stakes in the company. Divisadero Street Capital Management LP bought a new position in Establishment Labs during the 2nd quarter worth $5,829,000. Principal Financial Group Inc. acquired a new stake in shares of Establishment Labs in the second quarter valued at approximately $593,000. Bayesian Capital Management LP bought a new stake in shares of Establishment Labs during the first quarter valued at approximately $631,000. Sofinnova Investments Inc. boosted its position in shares of Establishment Labs by 204.1% during the second quarter. Sofinnova Investments Inc. now owns 429,244 shares of the company's stock worth $19,505,000 after buying an additional 288,082 shares during the period. Finally, Sei Investments Co. grew its holdings in Establishment Labs by 634.5% in the 2nd quarter. Sei Investments Co. now owns 40,576 shares of the company's stock worth $1,844,000 after buying an additional 35,052 shares in the last quarter. 72.91% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

ESTA has been the topic of a number of recent analyst reports. Stephens restated an "overweight" rating and set a $68.00 price objective on shares of Establishment Labs in a research note on Wednesday, August 7th. BTIG Research raised their price objective on shares of Establishment Labs from $62.00 to $65.00 and gave the company a "buy" rating in a research note on Monday, October 14th. JPMorgan Chase & Co. cut their target price on Establishment Labs from $61.00 to $50.00 and set an "overweight" rating for the company in a research report on Wednesday, August 7th. Finally, Citigroup lifted their price target on Establishment Labs from $45.00 to $50.00 and gave the company a "neutral" rating in a research report on Tuesday, October 1st. One equities research analyst has rated the stock with a hold rating and four have assigned a buy rating to the company's stock. Based on data from MarketBeat, Establishment Labs has a consensus rating of "Moderate Buy" and an average target price of $60.60.

Establishment Labs Stock Up 0.6 %

Shares of Establishment Labs stock traded up $0.26 during midday trading on Wednesday, hitting $45.83. The company's stock had a trading volume of 136,213 shares, compared to its average volume of 389,355. The firm has a market capitalization of $1.28 billion, a P/E ratio of -17.66 and a beta of 1.20. Establishment Labs Holdings Inc. has a 1-year low of $22.05 and a 1-year high of $60.12. The company has a quick ratio of 2.29, a current ratio of 3.62 and a debt-to-equity ratio of 5.94. The stock has a 50-day simple moving average of $43.01 and a 200-day simple moving average of $44.98.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.